Related Experiment Video
Updated: Oct 14, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
[A case of protein-losing gastroenteropathy in association with mixed connective tissue disease which was
K Nosho1, H Takahashi, Y Ikeda
1First Department of Internal Medicine, Sapporo Medical University School of Medicine.
Abstract:
A 47-year-old man had been given a diagnosis of mixed connective tissue disease (MCTD) on 1987 when he had presented with Raynaud's phenomenon, polyarthralgia, sclerodactyly, and a high titre of anti-RNP antibody. Once his symptoms had improved following the administration of prednisolone orally and the treatment was discontinued since 1995. He noticed dyspnea and chest pain in February 1997. The bilateral pleural effusion was pointed out in the local hospital and he was admitted to our hospital in March 1997 for further examination. In addition to pleural effusion and ascites, laboratory studies revealed hypoalbuminemia and low serum levels of complements. Renal and liver function tests were normal and the urine gave a trace test for protein. The presence of protein loss in the gut was confirmed by an elevated alpha 1-antitrypsin clearance and 99mTc-albumin scintigraphy showing abnormal radioactivity in the gastrointestinal tract. Although endoscopic examination showed no abnormal findings macroscopically and gastrointestinal biopsies revealed nonspecific inflammation only, immunofluorescent studies demonstrated deposits of C 3, C 4 and IgG in the stomach, colon, and pleura. These findings supported the pathogenesis that immune deposits in tissues caused protein-losing gastroenteropathy (PLGE) in MCTD. Intravenous administration of cyclophosphamide started since July 1997, while the high-dose corticosteroid therapy including methylprednisolone pulse therapy were not effective. Hypoalbuminemia and low serum levels of complements improved remarkably and the pleural effusion and ascites disappeared after cyclophosphamide pulse therapy four times monthly. Cyclophosphamide pulse therapy should be considered as a possibly effective treatment for PLGE in association with collagen disease resistant to corticosteroid therapy.
Insights
Mixed connective tissue disease (MCTD) can cause protein-losing gastroenteropathy (PLGE). Cyclophosphamide pulse therapy effectively treated PLGE in a patient resistant to corticosteroids.
Area of Science:
- Rheumatology
- Gastroenterology
- Immunology
Background:
- Mixed connective tissue disease (MCTD) is a rare autoimmune disorder.
- Protein-losing gastroenteropathy (PLGE) is a potential complication of MCTD.
Observation:
- A 47-year-old male with MCTD presented with dyspnea, chest pain, pleural effusion, and ascites.
- Laboratory findings included hypoalbuminemia and low complement levels, with evidence of protein loss in the gut.
- Immunofluorescence studies revealed immune deposits in the stomach, colon, and pleura.
Findings:
- The patient's PLGE was refractory to high-dose corticosteroid therapy.
- Cyclophosphamide pulse therapy led to remarkable improvement in hypoalbuminemia, complement levels, pleural effusion, and ascites.
Implications:
- Cyclophosphamide pulse therapy is a potential treatment for PLGE associated with collagen diseases.
- This case highlights the importance of considering immune complex deposition in the pathogenesis of PLGE in MCTD.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Pancreatitis II: Collaborative Care
Assessment:
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...